Financial Performance - Livzon Pharmaceutical Group reported a cash dividend of RMB 14.3 per 10 shares for the 2025 profit distribution plan[7]. - The company achieved operating revenue of CNY 12.02 billion in 2025, representing a year-on-year increase of 1.76%[22]. - Net profit attributable to shareholders was CNY 2.02 billion, a decrease of 1.84% compared to the previous year[22]. - The net profit after deducting non-recurring gains and losses was CNY 2.01 billion, reflecting a growth of 1.51% year-on-year[22]. - The company reported a total of CNY 14.08 million in non-recurring gains for 2025, compared to CNY 81.90 million in 2024[27]. - The company reported a gross profit margin of 65.90% for the pharmaceutical manufacturing sector, an increase of 0.45 percentage points compared to the previous year[77]. - The company reported a net profit of 1,712.13 million, with a revenue of 3,278.75 million, reflecting a strong performance in the pharmaceutical sector[121]. - The company reported a total cash outflow from investment activities surged by 729.99% year-on-year to ¥11,364,837,752.13, mainly due to an increase in structured deposit business[99]. Research and Development - The company invested approximately CNY 1.06 billion in R&D, accounting for 8.79% of total operating revenue[31]. - There are currently 40 formulation projects under research, with 12 in the listing application stage and 4 in Phase III clinical trials[31]. - The company is focusing on expanding its market presence in Brazil to overcome trade and policy barriers, enhancing operational efficiency[73]. - The company is committed to research and development, with a focus on new product innovation and technological advancements in the pharmaceutical sector[162]. - The company is advancing multiple projects in clinical trials, including the injection of semaglutide for type 2 diabetes and weight management, which are expected to enhance its metabolic product line[90]. - The company has received approval for multiple new products, including LZZG2101 for cardiovascular diseases and various reproductive health products, enhancing its product pipeline[90]. - The company’s R&D investment intensity and pipeline conversion efficiency are continuously improving, focusing on unmet clinical needs in chronic disease areas[66]. Corporate Governance - The company emphasizes the accuracy and completeness of its financial report, with the responsible persons affirming their legal accountability[5]. - Livzon Pharmaceutical Group's financial report is subject to audit by a registered accounting firm, ensuring compliance with regulatory standards[11]. - The company has a robust governance structure, including various committees to oversee compensation, audit, and environmental, social, and governance (ESG) matters[158]. - The board of directors strictly adhered to legal and regulatory requirements, ensuring diligent performance of their responsibilities[175]. - The company has established a structured public welfare management system to enhance drug accessibility and reduce production and distribution costs[55]. - The company has implemented a comprehensive ESG strategy, producing high-quality ESG reports for nine consecutive years[143]. - The company has established a data management platform for investor relations, enhancing communication and information dissemination[142]. Market Expansion and Internationalization - The company achieved overseas revenue of 1.93 billion yuan, a year-on-year increase of 11.97%, accounting for 16.06% of total revenue[44]. - The company signed sales cooperation agreements for its formulation products, covering over 50 countries, and successfully obtained market approvals in key emerging markets[46]. - The company is advancing its localization strategy in Southeast Asia and South America, leveraging local resources for innovative drug development[47]. - By 2026, the company plans to increase its overseas revenue share and expand its global presence through local operations and strategic partnerships[123]. - The company is pursuing strategic collaborations with leading global pharmaceutical companies to enhance its product commercialization efforts in regulated markets[129]. Risk Management - The company has established a financial derivative trading management system to control trading risks and ensure compliance with internal procedures[118]. - The company emphasizes risk management principles in foreign exchange derivative transactions to mitigate market and internal control risks[118]. - The company is enhancing its risk management and internal control systems, with a focus on professionalization and standardization of internal audit work[200]. - Risk management evaluations were conducted by department heads to assess the likelihood of risk occurrences and provide handling solutions[198]. - The company focuses on high-risk areas such as fund management, R&D, quality control, and sales operations in its risk management efforts[198]. Leadership and Management Changes - The company is undergoing significant management changes, including the resignation of several senior executives due to retirement or personal reasons[151]. - The company is focused on maintaining stability in its leadership while preparing for future growth and strategic initiatives[150]. - The company has a strong leadership team with diverse backgrounds in pharmaceuticals, finance, and management, including professionals with advanced degrees from prestigious institutions[161]. - The company has appointed independent non-executive directors with significant experience in auditing, corporate governance, and risk management to strengthen its board[156]. - The company’s board of directors has established a compensation and assessment committee to evaluate the performance of directors and senior management annually[191]. Employee and Compensation Policies - The company’s employee compensation policy is designed to ensure fairness and is linked to individual performance and company profitability[181]. - The total remuneration for Chairman Zhu Baoguo is CNY 3.25 million, while Executive Director Tang Yanggang received CNY 6.50 million[170]. - The company has a performance assessment system for senior management, which influences the distribution of performance bonuses and year-end double salaries[168]. - The company has not made any cash dividends during the reporting period, and the reasons for this are not applicable[186]. - The company has implemented a project management training program to enhance the efficiency of the R&D process[183]. Compliance and Regulatory Environment - The regulatory environment is becoming increasingly stringent, pushing the pharmaceutical industry towards standardized operations and compliance, which is critical for survival and competitiveness[65]. - The government has implemented policies to support innovation in the pharmaceutical sector, including a 30-day review channel for innovative drug clinical trials[59]. - The healthcare payment system is being refined to enhance drug accessibility and support the development of innovative products, with a focus on cost-effectiveness and clinical value[63]. - The company has maintained an A-level rating for information disclosure from the Shenzhen Stock Exchange for six consecutive years[141]. Innovation and Technology Integration - The company’s AI technology integration has significantly reduced the drug development cycle by over 50% in vaccine development and improved detection efficiency from 10 hours to 1 minute in quality control[51][52]. - The company is leveraging AI technology to transition its sales system from experience-driven to data-driven, improving marketing efficiency and service capabilities[53]. - AI technology will be integrated into production management to reduce costs and improve quality, optimizing processes and enhancing inventory management systems[132]. - The company aims to enhance its R&D capabilities by integrating AI technology across the entire drug development process, focusing on early drug discovery and clinical trial efficiency[126].

中集车辆（集团）股份有限公司 2025 年年度报告全文 中集车辆（集团）股份有限公司 2025 年年度报告 2026 年 3 月 1 中集车辆（集团）股份有限公司 2025 年年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责 任。 公司负责人李贵平先生、主管会计工作负责人及会计机构负责人占锐先生 (会计主管人员)声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告中涉及的未来发展计划等前瞻性陈述不构成公司对投资者的 实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解 计划、预测与承诺之间的差异。 本公司在本报告第四节"管理层讨论与分析"之"十一、公司未来发展 的展望"部分，详细阐述了公司经营中可能存在的风险及应对措施，敬请投资 者关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以 1,874,124,420 股为基 数，向全体股东每 10 股分派现金股利人民币 2.10 元（含税），不送红股，不 以公积 ...

Financial Performance - The company's operating revenue for 2025 reached ¥2,020,771,791.14, representing a 15.89% increase compared to ¥1,743,689,673.48 in 2024[18]. - Net profit attributable to shareholders for 2025 was ¥220,547,443.32, an increase of 11.57% from ¥197,683,033.96 in 2024[18]. - The basic earnings per share for 2025 was ¥0.47, reflecting an 11.90% increase from ¥0.42 in 2024[18]. - The total assets of the company at the end of 2025 amounted to ¥2,953,620,540.57, a 6.12% increase from ¥2,783,211,613.47 at the end of 2024[18]. - The net assets attributable to shareholders at the end of 2025 were ¥1,993,148,059.00, up 6.59% from ¥1,869,971,449.76 at the end of 2024[18]. - The net cash flow from operating activities for 2025 was ¥299,289,752.63, a decrease of 2.70% compared to ¥307,594,372.78 in 2024[18]. - The company reported a total revenue of 30,000 million for the reporting period[108]. - The net profit attributable to shareholders for the 2025 fiscal year was 220,547,443.32 CNY, with a parent company net profit of 202,466,067.75 CNY[141]. Market and Product Development - The company continues to focus on the development of composite reverse osmosis membranes and related technologies as part of its strategic initiatives[16]. - The company is focusing on expanding its product offerings in the membrane materials sector, with plans to enhance production capabilities through the establishment of a new subsidiary[89]. - The company aims to strengthen its market position in seawater desalination and special membranes, with ongoing efforts to optimize regional market coverage and expand into overseas markets[91]. - The company is actively involved in national projects aimed at advancing membrane technology, including key research on temperature-resistant organic membranes and urban wastewater resource utilization[40]. - The company is expanding its product offerings in the plant fiber business, focusing on customized furniture and health-oriented products, leveraging its brand recognition in the industry[35]. Research and Development - The company reported a total of 172 valid patents as of December 31, 2025, including 89 invention patents, indicating strong R&D capabilities[27]. - The company has a strong R&D innovation capability, with 172 valid patents, including 89 invention patents, ensuring its competitive edge in the membrane industry[40]. - The company is committed to investing in research and development to address the rising demand for high-throughput and water-saving products, which is crucial for maintaining its competitive edge[90]. - The company has established partnerships with three leading universities for collaborative research, enhancing its innovation capabilities[121]. Operational Strategy - The company’s operating strategy focuses on "large volume, low cost, high quality, strong R&D, and strong standards," driving high-quality development[31]. - The company is actively expanding its market presence through a direct sales and distribution model, enhancing customer service and support[31]. - The company has established a strong market position in the membrane separation industry, leveraging its leading R&D capabilities and system integration to enhance the economic value of its membrane systems[34]. - The company has a robust production and sales system, with nearly 1,000 sales outlets and a combination of direct sales, e-commerce, and group sales channels[35]. Financial Management - The company has implemented a dynamic adjustment of annual performance plans based on internal and external environments, enhancing its management efficiency[42]. - The company reported a significant increase of 255.63% in manufacturing costs for membrane separation engineering, reaching ¥3,131,791.36[58]. - The company’s cash and cash equivalents increased by 166,352,522.22 CNY, although this was a decrease of 15.69% compared to the previous year[69]. - The company has established and effectively implemented internal control systems to ensure compliance and safeguard assets, enhancing operational efficiency[143]. Governance and Compliance - The company has established a robust investor relations management system, utilizing multiple digital platforms for communication[105]. - The company has not reported any significant discrepancies between its governance practices and regulatory requirements[105]. - The company has implemented a diverse range of communication channels for investors, including online performance briefings and dedicated hotlines[105]. - The company maintains independence from its controlling shareholders in business, personnel, assets, and finance[106]. Risks and Challenges - The company has outlined potential risks and countermeasures in its future development outlook section of the management discussion[4]. - Risks include potential delays in receivables from membrane separation projects, which could adversely affect profitability[97]. - The competitive landscape in the membrane industry is intensifying, with challenges such as raw material price fluctuations and increased competition in the mid-to-low-end market[90]. Shareholder and Management Changes - Director Zheng Peng resigned due to work changes, effective August 18, 2025[109]. - The company appointed Wu Zongce as a director and vice general manager on February 25, 2025, due to a personnel change[110]. - The company has seen a turnover of independent directors, with Zhu Shan, Xu Xiang, and Liang Yu leaving due to term expiration on February 25, 2025[110]. - The company completed the election of the eighth board of directors and supervisory committee members on February 25, 2025[187]. Community and Environmental Initiatives - The company invested CNY 4.45 million in safety production in 2025, enhancing safety training and awareness among employees[152]. - The company supported the development of the local beef cattle industry, stabilizing the cattle stock at around 1,000 heads by the end of 2025[153]. - The company coordinated funding of CNY 722,400 for water reservoir resettlement projects, benefiting 163 households[153].

天津力生制药股份有限公司 2025 年年度报告全文 天津力生制药股份有限公司 2025 年年度报告 2026 年 3 月 25 日 1 天津力生制药股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人张平、主管会计工作负责人王家颖及会计机构负责人（会计 主管人员）高峻声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者 的实质承诺，敬请投资者注意投资风险。 应对措施：首先，公司坚持以市场需求为导向，加强市场研究，确保研 发方向与市场需求紧密贴合，研发管线能够满足目前及未来市场对产品的需 求。其次，公司具备强大的研发实力和持续的技术积累，着力打造高素质的 研发人才队伍，并注重完善薪酬体系和激励机制。最后，公司采取自主和合 作研发相结合的模式，加强与监管机构的沟通与合作，及时了解政策动态和 监管要求，确保全流程符合法规要求， ...

双林股份有限公司 2025 年年度报告全文 双林股份有限公司 2025 年年度报告 2026-005 2026-03-25 1 双林股份有限公司 2025 年年度报告全文 致股东的一封信 尊敬的各位股东朋友们： 时光奔涌，步履铿锵。我们刚刚携手走过了双林股份历史上承前启后、破局立新的一 年。2025 年，全球汽车产业在电动化与智能化的浪潮中加速重构，人工智能技术正以前所 未有的深度与实体产业融合。在此波澜壮阔的时代背景下，我谨代表公司全体同仁，向始 终信赖与支持我们的股东朋友们，致以最诚挚的感谢与敬意！ 深耕智造，以技术韧性穿越周期迷雾。2025 年，面对复杂多变的市场环境与激烈的行 业竞争，我们坚守汽车零部件主业，以技术创新构筑护城河。公司全年预计实现营业收入 稳健增长，盈利能力在行业承压背景下展现出强大韧性。这背后，是我们对核心技术的持 续投入：在智能座舱领域，我们的水平驱动器（HDM）持续领跑，配套车型不断拓展；在 新能源赛道，电驱动平台产品力与市场份额同步提升；轮毂轴承业务凭借技术优势，成功 切入更多主流新能源车型供应链。我们深知，唯有将技术做深、做透，才能在全球供应链 中占据不可替代的一席之地。 破 ...

华塑控股股份有限公司 2025 年年度报告全文 华塑控股股份有限公司 2025 年年度报告 2026 年 3 月 25 日 1 截至报告期末，公司母公司报表层面未分配利润-1,244,745,935.85 元， 合并报表层面未分配利润-1,216,486,575.10 元，未弥补亏损金额较大，结 合公司实际经营情况，可能存在较长时间内无法实施现金分红的风险。敬请 投资者关注该情形，并注意投资风险。 2 华塑控股股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人杨建安、主管会计工作负责人唐从虎及会计机构负责人（会 计主管人员）张静声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展计划等前瞻性陈述，不构成公司对投资者的实 质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解 计划、预测与承诺之间的差异。 公司在本报告第三节"管理层讨论与分析"之" ...

山东恒邦冶炼股份有限公司 2025 年年度报告全文 山东恒邦冶炼股份有限公司 2025 年年度报告 2026-012 2026 年 3 月 25 日 1 山东恒邦冶炼股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人曲胜利、主管会计工作负责人欧阳忠及会计机构负责人（会 计主管人员）牟晓垒声明：保证本年度报告中财务报告的真实、准确、完 整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来计划、业绩预测等方面的内容，均不构成公司对 投资者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并 且应当理解计划、预测与承诺之间的差异，请投资者注意投资风险。 本报告第三节"管理层讨论与分析"中描述了公司未来经营中可能存在 的风险及应对措施，敬请投资者关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以 1,429,970,408 股为 基数，向全体股东每 10 股派发现金红利 1.34 元（含税），送 ...

公司代码：603025 公司简称：大豪科技 北京大豪科技股份有限公司 2025 年年度报告 北京大豪科技股份有限公司2025 年年度报告 北京大豪科技股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、大信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人胡雄光、主管会计工作负责人周斌及会计机构负责人（会计主管人员）周斌声明： 保证年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 根据第五届董事会第五次会议决议，建议以总股本1,116,654,773股为基数，向全体股东每10 股派发现金股利4.5元（含税），共计支付现金股利502,494,647.85元。前述预案尚待2025年度股东 会批准。 截至报告期末，母公司存在未弥补亏损的相关情况及其对公司分红等事项的影响 □适用 √不适用 六、前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划 ...

中国化学工程股份有限公司 2025 年年度报告 公司代码：601117 公司简称：中国化学 中国化学工程股份有限公司 2025 年年度报告 1 中国化学工程股份有限公司 2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、中审众环会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人莫鼎革、主管会计工作负责人刘东进及会计机构负责人（会计主管人员）张学明 声明：保证年度报告中财务报告的真实、准确、完整。 本次利润分配将以实施权益分派股权登记日登记的总股本为基数，在实施权益分派的股权登 记日前公司总股本发生变动的，拟维持每股分配比例不变，相应调整分配总额。如后续总股本发 生变化，公司将另行公告具体调整情况。 截至报告期末，母公司存在未弥补亏损的相关情况及其对公司分红等事项的影响 □适用 √不适用 六、前瞻性陈述的风险声明 √适用 □不适用 本年度报告中所涉及的未来计划、发展战略等前瞻性陈述，不构成对投资者的实质性承诺， ...

星环信息科技（上海）股份有限公司2025 年年度报告 公司代码：688031 公司简称：星环科技 星环信息科技（上海）股份有限公司 2025 年年度报告 1 / 266 星环信息科技（上海）股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司上市时未盈利且尚未实现盈利 √是 □否 2025 年度，公司作为一家企业级 AI 和大数据基础设施软件开发商，构建大数据与云基础平 台、分布式数据库、数据开发工具、人工智能平台等软件产品矩阵，为企业高效构建 AI 基础设施， 全面赋能金融、政府、能源等多个行业进行数智化转型和业务范式创新。 公司的产品和服务面向领域众多，软件产品标准化程度较高。2025 年度，公司不断拓展新的 合作伙伴关系，和各类 CPU、GPU、操作系统、整机和硬件厂商进行产品适配和性能优化，包括 众多国内领先的技术企业，以共同促进核心技术领域国产化进程。同时，公司持续加大创新性投 入，在 2025 年产品发布会上，公司正式推出新一代 AI 基础设施，明确将 ...